Shield Therapeutics to Present at the Biotech Showcase 2011

WOLLERAU, Switzerland, January 7, 2011 /PRNewswire/ -- Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that Carl Sterritt, Chief Executive Officer, will present at the Biotech Showcase Conference on Wednesday 12 January, 2011 at 14:30 PST/ 22:30 GMT at the Parc 55 Wyndham Union Square Hotel in San Francisco, California.

About the Biotech Showcase(TM) (Innovation - Opportunity - Collaboration)

Now in its third year, Biotech Showcase(TM) will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. Public and private investors are always invited to attend the showcase on a complimentary basis. The Biotech Showcase(TM) was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit our website for more information: http://www.ebdgroup.com/bts/index.php.

About Shield

Shield, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently preparing to undertake a global pivotal Phase III study of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease. The Company is headquartered in Wollerau, Switzerland. For further information, please visit http://www.shieldtherapeutics.com.

    For more information about Shield, please contact:

    M:Communications
    Mary-Jane Elliott / Emma Thompson / Nick Francis
    Tel +44(0)20-7920-2345
    E-mail: [email protected]

SOURCE Shield Therapeutics